Grace Therapeutics GRCE Income Statement (2017-2026)

NASDAQ GRCE
$2.14 +0.02 (+0.94%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Grace Therapeutics Quarterly Income Statement

Periods 32 quarters
Latest Jun 2026

Grace Therapeutics reported net income of -$15.79M for the quarter ended Jun 2026. This income statement covers 32 quarters of results from Feb 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Feb2017 Mar2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
5.46M7.38M6.14M7.42M7.44M7.44M7.44M7.44M7.55M9.40M9.40M10.14M10.14M10.14M13.72M13.83M14.13M15.47M16.02M16.27M
Revenue & cost
Revenue
Gross Profit
Operating items
Research & DevelopmentR&D
0.58M2.18M2.33M2.59M3.29M2.45M1.64M1.09M0.46M1.44M1.69M2.71M2.98M2.19M1.63M0.95M0.57M0.46M0.42M0.70M
Wages, Salaries and OtherWages
1.49M0.98M0.65M0.61M0.99M1.10M0.87M1.55M0.90M
Selling, General & AdministrativeSG&A
2.96M1.81M1.82M1.92M1.68M1.59M2.43M1.87M1.63M1.60M1.58M2.25M1.85M1.51M1.55M2.13M1.96M1.99M2.59M1.69M
Restructuring CostsRestructuring
1.49M
Operating ExpensesOpex
3.54M3.99M4.15M4.51M4.97M4.04M4.07M4.45M2.09M3.04M3.26M4.96M4.83M3.70M3.18M3.09M2.53M2.45M3.01M2.38M
Operating IncomeOp. Inc
-3.57M-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M
EBIT
-3.57M-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M
Non-operating items
Non Operating Interest Expenses
Interest & Investment IncomeInt & Inv Inc
0.01M0.04M0.03M0.04M0.07M0.11M0.13M0.21M0.32M0.25M0.23M0.17M0.14M0.17M0.20M0.17M0.17M0.14M0.14M
Other Non Operating IncomeOther Non Op Inc.
1.10M-0.17M-0.25M-0.08M-0.01M-0.01M-1.24M0.01M-0.01M0.00M-0.54M-0.01M0.01M-0.02M0.48M0.01M-0.01M0.00M-0.00M-0.01M
Non Operating IncomeNon Op. Inc.
4.55M0.70M-0.15M-0.04M0.02M0.08M0.12M0.14M-1.63M0.44M-0.79M1.62M0.55M-1.06M2.80M-0.27M1.59M0.13M0.13M0.13M
Net income details
EBT
0.98M-3.78M-4.55M-4.77M-5.08M-4.16M-37.96M-4.31M-3.72M-2.60M-4.05M-3.34M-4.28M-4.76M-0.38M-3.36M-0.94M-2.31M-2.88M-15.79M
Tax ProvisionsTaxes
-2.77M-0.24M-0.15M-0.27M-13.10M-0.29M-0.45M-0.21M-2.14M-0.72M-0.85M-0.60M-1.02M-1.99M
Profit After TaxPAT
0.98M-3.78M-7.82M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.31M-1.18M-15.79M
Income from Continuing OperationsIncome (Continuing)
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-24.86M-4.02M-3.27M-2.39M-1.91M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.31M-0.89M-15.79M
Consolidated Net IncomeConsol Net Inc.
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-24.86M-4.02M-3.27M-2.39M-1.91M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.31M-0.89M-15.79M
Income towards Parent CompanyParent Net Inc
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-24.86M-4.02M-3.27M-2.39M-1.91M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.31M-0.89M-15.79M
Net Income towards Common StockholdersNet Income
0.98M-3.78M-1.78M-4.52M-4.93M-3.89M-24.86M-4.02M-3.27M-2.39M-1.91M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.31M-0.89M-15.79M
Additional items
EPS (Basic)
0.18-0.51-0.29-0.61-0.66-0.52-3.34-0.54-0.43-0.21-0.20-0.24-0.30-0.360.05-0.21-0.06-0.14-0.05-0.91
EPS (Diluted)
0.18-0.51-0.29-0.61-0.66-0.52-3.34-0.54-0.43-0.21-0.20-0.24-0.30-0.360.05-0.21-0.06-0.14-0.05-0.91
Shares Outstanding
5.46M7.38M6.14M7.39M7.43M7.44M7.44M7.44M7.55M11.51M9.53M10.93M11.51M11.51M12.09M15.92M15.92M16.93M16.51M17.27M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
5.46M7.38M6.14M7.39M7.43M7.44M7.44M7.44M7.55M11.51M9.53M10.93M11.51M11.51M12.09M15.92M15.92M16.93M16.51M17.27M
EBITDA
-3.57M-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M
Interest ExpensesInt Expense
Tax Rate
60.945.083.056.5834.516.7011.998.0052.8021.6719.8912.71266.4969.25